Allogeneic Mesenchymal Stem Cells for Treatment of Experimental Autoimmune Encephalomyelitis
Open Access
- 1 October 2009
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 17 (10), 1799-1803
- https://doi.org/10.1038/mt.2009.157
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent MannerThe Journal of Immunology, 2009
- Mesenchymal Stromal Cells Engineered to Express Erythropoietin Induce Anti-erythropoietin Antibodies and Anemia in AllorecipientsMolecular Therapy, 2009
- Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 inductionBlood, 2008
- IFNgamma and B7-H1 in the immunology of mesenchymal stem cells.Cell Research, 2008
- Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric OxideCell Stem Cell, 2008
- Immunomodulatory properties of mesenchymal stromal cellsBlood, 2007
- Allogeneic marrow stromal cells are immune rejected by MHC class I– and class II–mismatched recipient miceBlood, 2005
- Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergyBlood, 2005
- Human mesenchymal stem cells modulate allogeneic immune cell responsesBlood, 2005
- Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradationBlood, 2004